Reliv’ International (OTCMKTS:RELV) and AEON Biopharma (NASDAQ:AEON) Critical Survey

AEON Biopharma (NASDAQ:AEON) and Reliv’ International (OTCMKTS:RELV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Profitability

This table compares AEON Biopharma and Reliv’ International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Reliv’ International	-0.61%	-1.89%	-1.31%

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 7.7% of Reliv’ International shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Comparatively, 30.0% of Reliv’ International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

AEON Biopharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500.

Valuation & Earnings

This table compares AEON Biopharma and Reliv’ International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.05
Reliv’ International	$35.06 million	0.09	-$440,000.00	($0.09)	-20.33

Reliv’ International has higher revenue and earnings than AEON Biopharma. Reliv’ International is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for AEON Biopharma and Reliv’ International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Reliv’ International	0	0	0	0	0.00

Summary

AEON Biopharma beats Reliv’ International on 8 of the 13 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.